TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Venus Concept ( (VERO) ) has issued an announcement.
On November 30, 2025, Venus Concept Inc. and its subsidiaries entered into a Consent Agreement with Madryn Health Partners to waive certain liquidity requirements and allow cash interest payments to be applied to outstanding principal balances. Additionally, a Twenty Second Bridge Loan Amendment was agreed upon, extending the maturity date and waiving liquidity requirements until December 31, 2025. The company also secured a Fourteenth Delayed Drawdown of $1.5 million on November 25, 2025, intended for general working capital purposes.
The most recent analyst rating on (VERO) stock is a Sell with a $2.00 price target. To see the full list of analyst forecasts on Venus Concept stock, see the VERO Stock Forecast page.
Spark’s Take on VERO Stock
According to Spark, TipRanks’ AI Analyst, VERO is a Underperform.
Venus Concept’s stock score is primarily impacted by its weak financial performance, characterized by declining revenues, high operating losses, and significant debt burdens. Technical analysis indicates bearish momentum, with the stock trading below key moving averages. The valuation is unattractive due to a negative P/E ratio and lack of dividend yield. Despite some positive developments in the earnings call, such as the launch of Venus Nova, the overall financial outlook remains uncertain.
To see Spark’s full report on VERO stock, click here.
More about Venus Concept
Average Trading Volume: 634,506
Technical Sentiment Signal: Strong Sell
Current Market Cap: $3.44M
For a thorough assessment of VERO stock, go to TipRanks’ Stock Analysis page.